What effect does semaglutide have on your eyes?

Does semaglutide cause diabetic retinopathy to worsen?

This is a question our prescribers hear most weeks, and the honest answer is: it can accelerate existing retinopathy in some people with diabetes, particularly those whose blood sugar drops quickly at the start of treatment. The STEP 1 trial (published in the New England Journal of Medicine) and the earlier SUSTAIN-6 cardiovascular trial both recorded higher rates of diabetic retinopathy complications in the semaglutide arm compared with placebo, though the absolute numbers were small.

The likely mechanism is the same one seen with rapid glucose lowering in diabetes more broadly. When blood sugar falls quickly, blood flow and pressure changes within the retinal vessels can destabilise lesions that were already present. Semaglutide doesn't cause retinopathy from scratch in people who don't have it — it is the speed of glucose change in an already-compromised eye that creates the problem.

For people using semaglutide for weight management who have no diabetes history, the retinopathy signal is far less prominent. That said, pre-diabetes is common in people seeking treatment, so baseline retinal health is worth discussing with your GP before starting, and our semaglutide and eyes page goes into greater depth on how the medicine interacts with ocular health across different patient groups. You can read more about the broader effects that semaglutide has on the body on the effects of semaglutide page.

What about blurred vision and other eye symptoms in people without diabetes?

Blurred vision and visual disturbances appear in the side-effect profiles published by regulators and in post-marketing reports, not only in people with diabetes. The NHS semaglutide medicines page lists blurred vision as a side effect to be aware of. In most cases this is transient, it tends to coincide with appetite suppression and early fluid shifts, and settles as the body adjusts.

A rarer but more serious concern is non-arteritic anterior ischaemic optic neuropathy, or NAION, a condition where blood supply to the optic nerve is suddenly reduced, causing painless vision loss in one eye. A 2024 study published in JAMA Ophthalmology found a statistically higher incidence of NAION in semaglutide users compared with controls, though the overall incidence remains low. Regulatory agencies including the MHRA have noted this signal and continue to monitor it; it does not constitute a contraindication but is a reason to report any sudden one-sided vision loss immediately.

Semaglutide also influences the brain's reward and satiety circuits, which is a separate mechanism explored on the semaglutide effect on the brain page, relevant context for understanding how a GLP-1 medicine affects multiple systems simultaneously.

Who is most at risk, and what should you watch for?

The risk profile is not uniform. People with longstanding, poorly controlled type 2 diabetes and established diabetic retinopathy face the most meaningful risk from semaglutide's glucose-lowering speed. Ophthalmology review before and during treatment is recommended for this group. People with no diabetes history, good baseline eye health, and who are using semaglutide for weight management sit at the lower end of the risk spectrum, though they are not exempt from the rarer optic nerve concerns noted above.

Symptoms that require same-day medical attention, not a wait-and-see approach: sudden loss of vision in one or both eyes, new floaters or flashes of light, a shadow or curtain across your visual field, or any rapid deterioration in visual sharpness. Blurring that comes and goes mildly in the first few weeks is more likely to be benign, but mention it at your next clinical review regardless.

Suspected side effects (including eye symptoms) can be reported directly to the MHRA via the Yellow Card scheme, and clinicians as well as patients are encouraged to do so. This data is how safety signals like the NAION link were first identified. If you're weighing up Wegovy's overall benefit and risk profile, the full effects of Wegovy page covers the wider picture.

Should eye symptoms change your decision about starting or continuing treatment?

Not necessarily, but they should inform a proper clinical conversation. For most people seeking weight management who have no retinal disease, the eye risks do not outweigh the well-documented cardiovascular and metabolic benefits of semaglutide. The decision belongs with a prescriber who knows your full medical history, not with a general risk statement.

If you have existing retinal disease, your ophthalmologist and prescribing clinician should coordinate. Dose titration may be more gradual to moderate the speed of glucose reduction. If you already take semaglutide and notice any vision change, even one that seems mild, note when it started and whether it's in one eye or both, that detail matters clinically.

Wegovy's full prescribing context, including eligibility criteria and what a clinical assessment covers, is on our Wegovy page. For anyone thinking about starting treatment and wanting to understand the private route, the consultation page explains how to have your suitability assessed by a GPhC-registered prescriber. On cost, the Wegovy price comparison page sets out what private treatment typically involves. Check your eligibility and speak to a prescriber who can review your eye history alongside everything else.